Anixa Biosciences Inc — Director's Dealing 2017

Jul 25, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ITUS Corp (ITUS)
CIK: 0000715446
Period of Report: 2017-07-17

Reporting Person: Titterton Lewis H jr (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	782144	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Options (Right to Buy)	$2.58	2017-11-30	Common Stock (2400)		Direct
Employee Stock Options (Right to Buy)	$2.58	2023-11-08	Common Stock (120000)		Direct
Employee Stock Options (Right to Buy)	$2.58	2023-12-31	Common Stock (16000)		Direct
Employee Stock Options (Right to Buy)	$2.58	2025-01-02	Common Stock (16000)		Direct
Employee Stock Options (Right to Buy)	$2.92	2026-01-14	Common Stock (16000)		Direct
Employee Stock Options (Right to Buy)	$0.82	2027-07-17	Common Stock (6000)		Direct
Employee Stock Options (Right to Buy)	$2.58	2022-09-19	Common Stock (30000)		Direct
Employee Stock Options (Right to Buy)	$2.58	2023-02-15	Common Stock (40000)		Direct
Employee Stock Options (Right to Buy)	$2.58	2022-12-31	Common Stock (16000)		Direct
Common Stock Purchase Warrant	$10	2019-07-15	Common Stock (2000)		Direct

Footnotes

F1: Right-To-Buy pursuant to the ITUS Corporation 2010 Share Incentive Plan.

F2: The option vests and becomes exercisable 50% on September 30, 2017 and 50% on December 31, 2017.

F3: Right-To-Buy pursuant to stock options that were not granted under the ITUS Corporation 2010 Share Incentive Plan.

F4: Pursuant to a public offering by ITUS Corporation in July 2014.